Arcoris Bio raises €6.7M in biomarker detection funding
Also see more funding coverage: /funding/
Founded 2022 · Schlieren, Switzerland
The European life sciences sector continues to attract significant venture capital as investors recognise the continent’s strengths in precision medicine and regulatory expertise. The latest validation comes from Switzerland, where Arcoris Bio has secured €6.7 million in seed funding to advance its biomarker detection platform. This funding round positions the Schlieren-based startup to capitalise on growing demand for personalised healthcare solutions across Europe’s fragmented but innovation-hungry markets.
The biomarker detection funding was co-led by Ventura Ace and ZEISS Ventures, signalling strong confidence from both pure-play venture capital and strategic corporate investment. This investor combination reflects the maturation of European life sciences venture capital, where traditional VCs increasingly partner with corporates that bring both capital and industry expertise.
Strategic investors back biomarker detection innovation
ZEISS Ventures’ participation is particularly noteworthy, as the German optics giant’s venture arm has been selectively investing in companies that complement its precision measurement and healthcare imaging capabilities. Their involvement suggests Arcoris Bio’s technology could integrate with existing diagnostic workflows that ZEISS serves across European healthcare systems.
Ventura Ace’s co-leadership reinforces the trend of European VCs backing deep-tech life sciences companies despite longer development cycles. The firm’s thesis centres on backing European founders who can navigate complex regulatory environments whilst building globally competitive technologies.
“We’re seeing unprecedented opportunities in biomarker detection as European healthcare systems embrace precision medicine,” noted a source familiar with the investment. “Arcoris Bio’s platform addresses real clinical needs whilst leveraging Switzerland’s regulatory advantages.”
Swiss biotech advances personalised medicine platform
Arcoris Bio’s biomarker detection platform represents a sophisticated approach to personalised healthcare, utilising advanced analytics to identify biological markers that can guide treatment decisions. The company benefits from Switzerland’s position as a global life sciences hub, with access to world-class research institutions and a regulatory environment that facilitates innovation.
The funding will accelerate platform development and support expansion into key European markets, where demand for precision diagnostic tools continues growing. Switzerland’s bilateral agreements with the EU provide Arcoris Bio with advantageous access to European healthcare markets whilst maintaining operational flexibility.
Founded recently, the company has already demonstrated technical feasibility of its approach, positioning it well for the typically lengthy validation process required in life sciences. The startup’s location in Schlieren, near Zurich’s thriving biotech cluster, provides access to both talent and established industry networks.
This funding signals continued investor appetite for European life sciences companies that combine technical innovation with clear regulatory pathways. As healthcare systems across Europe increasingly adopt precision medicine approaches, companies like Arcoris Bio are well-positioned to capture growing market opportunities whilst navigating the continent’s complex but ultimately rewarding regulatory landscape.
